Display options
Cite
Kostakoglu L, Cheson BD. State-of-the-Art Research on "Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response". Front Oncol. 2013;3:212doi: 10.3389/fonc.2013.00212.
Kostakoglu, L., & Cheson, B. D. (2013). State-of-the-Art Research on "Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response". Frontiers in oncology, 3212. https://doi.org/10.3389/fonc.2013.00212
Kostakoglu, Lale, and Cheson, Bruce D. "State-of-the-Art Research on "Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response"." Frontiers in oncology vol. 3 (2013): 212. doi: https://doi.org/10.3389/fonc.2013.00212
Kostakoglu L, Cheson BD. State-of-the-Art Research on "Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response". Front Oncol. 2013 Sep 04;3:212. doi: 10.3389/fonc.2013.00212. PMID: 24027671; PMCID: PMC3762124.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2013 Sep 04;3:212. doi: 10.3389/fonc.2013.00212.

State-of-the-Art Research on "Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response".

Frontiers in oncology

Lale Kostakoglu, Bruce D Cheson

Affiliations

  1. Department of Radiology, Mount Sinai Medical Center , New York, NY , USA.

PMID: 24027671 PMCID: PMC3762124 DOI: 10.3389/fonc.2013.00212

Abstract

Lymphomas are heterogeneous but potentially curable group of neoplasms. Treatment of lymphomas has rapidly evolved overtime with significant improvement in the cure rate and reductions in treatment-related toxicities. Despite excellent results, treatment programs are continued to be developed to achieve better curative and safety profiles. In these patients individualized therapy schemes can be devised based on a well-defined risk categorization. The therapy efficacy can be increased early during therapy in non-responding patients with escalated therapy protocols or with the addition of radiation therapy, particularly, in advanced-stage or unfavorable risk patients. The increasing availability of positron emission tomography using 18F-fluorodeoxyglucose, particularly fused with computed tomography (FDG-PET/CT) has lead to the integration of this modality into the routine staging and restaging for lymphoma with convincing evidence that it is a more accurate imaging modality compared with conventional imaging techniques. FDG-PET/CT is also is a promising surrogate for tumor chemosensitivity early during therapy. This review will summarize published data on the utility of FDG-PET/CT imaging in the staging, restaging, and predicting therapy response in patients with lymphoma.

Keywords: Hodgkin lymphoma; PET/CT; interim-PET; non-Hodgkin lymphoma; response surrogate

References

  1. J Clin Oncol. 2011 Aug 10;29(23):3194-200 - PubMed
  2. Leuk Lymphoma. 2000 Nov;39(5-6):543-53 - PubMed
  3. Cancer. 2006 Dec 1;107(11):2678-87 - PubMed
  4. Bone Marrow Transplant. 1997 Jul;20(1):21-6 - PubMed
  5. Cancer. 2001 Jan 15;91(2):302-10 - PubMed
  6. J Clin Oncol. 2005 Jul 20;23(21):4643-51 - PubMed
  7. J Nucl Med. 2005 Jun;46(6):958-63 - PubMed
  8. J Clin Oncol. 1989 Nov;7(11):1630-6 - PubMed
  9. Ann Oncol. 2000 Oct;11(10):1273-9 - PubMed
  10. Ann Oncol. 2005 Mar;16(3):473-80 - PubMed
  11. Blood. 1998 May 1;91(9):3340-6 - PubMed
  12. J Clin Oncol. 2012 Dec 20;30(36):4508-14 - PubMed
  13. J Nucl Med. 2006 Oct;47(10):1643-8 - PubMed
  14. Ann Oncol. 2011 Mar;22(3):671-680 - PubMed
  15. J Nucl Med. 2005 Apr;46(4):608-13 - PubMed
  16. Ann Hematol. 2012 May;91(5):697-703 - PubMed
  17. Radiol Med. 2008 Jun;113(4):578-90 - PubMed
  18. Ann Oncol. 2006 Aug;17(8):1296-300 - PubMed
  19. J Nucl Med. 2006 Aug;47(8):1267-73 - PubMed
  20. Eur J Nucl Med Mol Imaging. 2006 Sep;33(9):1025-31 - PubMed
  21. Q J Nucl Med Mol Imaging. 2011 Oct;55(5):567-75 - PubMed
  22. Curr Treat Options Oncol. 2003 Aug;4(4):297-305 - PubMed
  23. Eur J Nucl Med Mol Imaging. 2011 Jul;38(7):1191-202 - PubMed
  24. Haematologica. 2001 Mar;86(3):266-73 - PubMed
  25. J Nucl Med. 2010 Sep;51(9):1337-43 - PubMed
  26. Ann Oncol. 2002 Sep;13(9):1356-63 - PubMed
  27. Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):156-62 - PubMed
  28. Leuk Lymphoma. 2009 Aug;50(8):1257-60 - PubMed
  29. Clin Nucl Med. 2011 Jul;36(7):553-9 - PubMed
  30. Leuk Lymphoma. 2012 Nov;53(11):2143-50 - PubMed
  31. Ann Oncol. 2011 Apr;22(4):910-915 - PubMed
  32. Blood. 2007 Jan 15;109(2):486-91 - PubMed
  33. Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):4-12 - PubMed
  34. J Clin Oncol. 2007 Aug 20;25(24):3746-52 - PubMed
  35. Oncol Rep. 2001 Nov-Dec;8(6):1393-9 - PubMed
  36. J Clin Oncol. 2007 Jun 10;25(17):2426-33 - PubMed
  37. Eur J Nucl Med Mol Imaging. 2010 Dec;37(12):2307-14 - PubMed
  38. Leuk Lymphoma. 2012 Jan;53(1):64-70 - PubMed
  39. Cancer. 2007 Aug 1;110(3):652-9 - PubMed
  40. Br J Haematol. 2010 Jul;150(1):39-45 - PubMed
  41. Ann Oncol. 2009 Mar;20(3):508-12 - PubMed
  42. Ann Hematol. 2002 Jan;81(1):20-5 - PubMed
  43. Br J Cancer. 2004 Feb 9;90(3):620-5 - PubMed
  44. J Clin Oncol. 2010 Apr 10;28(11):1896-903 - PubMed
  45. Br J Haematol. 2010 Mar;148(6):890-7 - PubMed
  46. Eur J Nucl Med Mol Imaging. 2010 Aug;37(9):1633-42 - PubMed
  47. J Nucl Med. 2007 Oct;48(10):1626-32 - PubMed
  48. J Clin Oncol. 2001 Jan 15;19(2):414-9 - PubMed
  49. Nuklearmedizin. 1997 Oct;36(7):234-9 - PubMed
  50. Eur J Nucl Med Mol Imaging. 2009 Nov;36(11):1813-21 - PubMed
  51. Ann Oncol. 2004 Nov;15(11):1699-704 - PubMed
  52. Eur J Nucl Med Mol Imaging. 2011 Jun;38(6):1064-71 - PubMed
  53. Ann Oncol. 2007 Oct;18(10):1685-90 - PubMed
  54. Ann Oncol. 2008 Oct;19(10):1770-3 - PubMed
  55. Eur J Nucl Med Mol Imaging. 2011 Aug;38(8):1469-76 - PubMed
  56. Cancer J. 2009 Mar-Apr;15(2):161-3 - PubMed
  57. Eur J Haematol. 2007 Sep;79(3):205-9 - PubMed
  58. Hematol Oncol Clin North Am. 2008 Oct;22(5):863-82, viii - PubMed
  59. Ann Oncol. 2006 Jan;17(1):117-22 - PubMed
  60. Blood. 2007 Aug 15;110(4):1278-82 - PubMed
  61. Ann Hematol. 2011 Nov;90(11):1329-36 - PubMed
  62. Clin Lymphoma Myeloma Leuk. 2011 Jun;11(3):261-6 - PubMed
  63. Eur J Nucl Med Mol Imaging. 2007 Jan;34(1):60-7 - PubMed
  64. J Nucl Med. 2010 Jan;51(1):25-30 - PubMed
  65. Oncologist. 2010;15(7):750-9 - PubMed
  66. Cancer. 2001 Mar 1;91(5):889-99 - PubMed
  67. Acta Radiol. 1996 May;37(3 Pt 1):323-6 - PubMed
  68. Ann Oncol. 2010 Jan;21(1):126-32 - PubMed
  69. Blood. 2010 Dec 2;116(23):4934-7 - PubMed
  70. Cancer. 2005 Sep 1;104(5):1066-74 - PubMed
  71. Lancet. 2011 Jan 1;377(9759):42-51 - PubMed
  72. J Clin Oncol. 1994 May;12(5):1074-84 - PubMed
  73. Ann Oncol. 1999 Oct;10(10):1181-4 - PubMed
  74. Eur J Haematol. 2006 Jun;76(6):473-80 - PubMed
  75. Blood. 2011 Jul 7;118(1):37-43 - PubMed
  76. Blood. 2006 Jan 1;107(1):52-9 - PubMed
  77. J Clin Oncol. 2012 Dec 10;30(35):4317-22 - PubMed
  78. Haematologica. 2006 Apr;91(4):475-81 - PubMed
  79. Br J Haematol. 2011 Mar;152(5):551-60 - PubMed
  80. J Clin Oncol. 2007 Feb 10;25(5):579-86 - PubMed
  81. J Clin Oncol. 2009 Apr 10;27(11):1906-14 - PubMed
  82. Blood. 2005 Aug 15;106(4):1376-81 - PubMed
  83. Radiology. 2005 Dec;237(3):1038-45 - PubMed
  84. Ann Oncol. 2005 Jul;16(7):1160-8 - PubMed
  85. Ann Oncol. 2006 Dec;17(12):1761-5 - PubMed
  86. J Clin Oncol. 1988 Jun;6(6):940-6 - PubMed
  87. Leuk Lymphoma. 2007 Aug;48(8):1548-55 - PubMed
  88. Cancer. 2002 Mar 1;94(5):1522-31 - PubMed
  89. Biol Blood Marrow Transplant. 2011 Nov;17(11):1646-52 - PubMed
  90. Ann Oncol. 2005 Sep;16(9):1514-23 - PubMed
  91. Ann Oncol. 2006 May;17(5):780-4 - PubMed
  92. Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1164-71 - PubMed
  93. Ann Oncol. 2009 May;20 Suppl 4:108-9 - PubMed
  94. Leuk Lymphoma. 1999 Aug;34(5-6):545-51 - PubMed
  95. J Nucl Med. 2013 May;54(5):683-90 - PubMed
  96. Am J Hematol. 2012 Jan;87(1):32-6 - PubMed
  97. Radiology. 1998 Feb;206(2):475-81 - PubMed
  98. Cancer Treat Rep. 1977 Sep;61(6):1023-7 - PubMed
  99. J Clin Oncol. 2009 Apr 10;27(11):1781-7 - PubMed
  100. Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):1824-33 - PubMed
  101. J Nucl Med. 2008 Jan;49(1):13-21 - PubMed
  102. Leuk Lymphoma. 2008 Sep;49(9):1693-701 - PubMed
  103. Ann Hematol. 2007 Dec;86(12):897-903 - PubMed
  104. Cancer. 2010 Aug 15;116(16):3835-42 - PubMed
  105. Leuk Lymphoma. 2012 Mar;53(3):381-5 - PubMed
  106. Br J Haematol. 2003 Oct;123(2):282-7 - PubMed
  107. Ann Hematol. 2011 Feb;90(2):165-71 - PubMed
  108. Nucl Med Commun. 1998 Nov;19(11):1055-63 - PubMed
  109. Blood. 2012 Feb 16;119(7):1665-70 - PubMed
  110. Cancer Sci. 2012 Mar;103(3):477-82 - PubMed
  111. Blood. 2003 May 15;101(10):3875-6 - PubMed
  112. Ann Oncol. 2001 Jun;12(6):825-30 - PubMed
  113. Haematologica. 2006 Apr;91(4):482-9 - PubMed
  114. Eur J Nucl Med Mol Imaging. 2003 May;30(5):682-8 - PubMed
  115. Radiology. 2004 Sep;232(3):823-9 - PubMed
  116. Rev Esp Med Nucl. 2005 Mar-Apr;24(2):107-12 - PubMed
  117. Blood. 2011 May 19;117(20):5314-20 - PubMed
  118. J Clin Oncol. 2007 Feb 10;25(5):571-8 - PubMed
  119. Cancer Sci. 2011 Feb;102(2):414-8 - PubMed
  120. Eur J Radiol. 2012 Feb;81(2):303-11 - PubMed
  121. Ann Oncol. 1998 Oct;9(10):1117-22 - PubMed
  122. Ann Oncol. 2009 Feb;20(2):309-18 - PubMed
  123. J Clin Oncol. 2009 Apr 10;27(11):1742-3 - PubMed
  124. Am J Med. 2002 Mar;112(4):262-8 - PubMed

Publication Types